Company Overview and News
2018-10-16 seekingalpha - 1
Annaly Capital Management is a promising high-yield income vehicle for investors with an above-average risk tolerance.
2018-10-13 247wallst - 1
October 12, 2018: Here are four stocks trading with heavy volume among 465 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.35 to 1, and on the Nasdaq, advancers led decliners by about 1.44 to 1.
F NLY GM MS
In the latest trading session, Annaly Capital Management (NLY - Free Report) closed at $10.11, marking a -0.79% move from the previous day. This move was narrower than the S&P 500's daily loss of 3.29%. Meanwhile, the Dow lost 3.15%, and the Nasdaq, a tech-heavy index, lost 4.08%.
SAB SJI NLY SJIU SAR SAQ
2018-10-10 sec.gov - 3
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
I am projecting AGNC will report a combined notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the third quarter of 2018.
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW WMC NRZ AIC CYS TRI MTGE MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC HTS IVR NYMT FMCCS FMCCT
2018-10-09 seekingalpha - 3
There are now 5 preferred shares from Annaly Capital Management (NLY) because NLY bought MTGE Investment Corp. (MTGE) and MTGEP became NLY-H. Currently, all of the NLY preferred shares - NLY.PF, NLY.PG, NLY.PC, NLY.PD, NLY.PH - are sitting in the hold range.
Fairly similar to the prior quarter, I am projecting AGNC will report a modest-notable gain regarding the company’s derivative instruments and other securities for the third quarter of 2018.
NYMTO ORC CHMI NYMTP AI TWO AGNC AIW NRZ AIC NLY CYS ARR NYMT
Top 10 10%+ "Safer" Dividend WallStar annual yields ranged from 11.65% to 24.87%. Their free cash flow yields ranged from 13.01% to 77.86%.
CPLP SXCP ANH ORC EARN WMC SNMP TCRX DX NLY TCRD TCRZ TSLF GMLP GPP
This series projects AGNC’s income statement for the third quarter of 2018. These projections help readers understand how most of the fixed-rate agency mREIT sector performed (valuable insight).
NYMTO ORC CHMI NYMTP AI AGNC AIW MO NRZ AIC NLY CYS ARR HTS NYMT
BDCL is a 2x Leveraged High-Yield ETN that could have a place in a portfolio constrained to only hold securities with current yields above 15%.
FSFR ARCC MAIN NLY NYTAB BBDC NEWTZ MORL ARU OCSI MSCA.CL MSCA CSWC TSLX NEWT NEWTL
Making its debut on 03/11/2013, smart beta exchange traded fund Global X SuperDividend U.S. ETF (DIV - Free Report) provides investors broad exposure to the Total Market (U.S.) ETFs category of the market.
DIV EAT NLY SDIV NCMI
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
2018-09-24 seekingalpha - 1
This article compares NLY’s recent dividend per share rates, yield percentages, and several dividend sustainability metrics to 19 mREIT peers.
ANH NYMTO ORC CHMI NYMTP AI CIM CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET